First Dual Aromatase-Steroid Sulfatase Inhibitors

摘要

Aromatase inhibitors in clinical use block the biosynthesis of estrogens. Hydrolysis of estrone 3-sulfate by steroid sulfatase is an important additional source of tumor estrogen, and blockade of both enzymes should provide a more effective endocrine therapy. Sulfamoylated derivatives of the aromatase inhibitor YM511 inhibited sulfatase and aromatase in JEG-3 cells with respective IC_(50) values of 20-227 and 0.82-100 nM (cf.letrozole, 0.89 nM). One dual inhibitor was potent against both enzymes in vivo, validating the concept.